Emergent BioSolutions | EBS - Trade Creditors


Emergent BioSolutions reported $112.2M in Trade Creditors for its fiscal quarter ending in December of 2023.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 44.57M 32.32M Jun/2026
Akebia Therapeutics USD 9.42M 1.04M Jun/2026
ALKERMES USD 142.86M 40.5M Jun/2026
Alnylam Pharmaceuticals USD 135.4M 27.38M Sep/2026
Amarin USD 40.43M 21.63M Sep/2026
ANI Pharmaceuticals USD 73.83M 4.14M Jun/2026
BioMarin Pharmaceutical USD 913.67M 120.52M Jun/2026
Coherus Biosciences USD 13.17M 1.69M Jun/2026
Emergent BioSolutions USD 112.2M 500K Dec/2023
Exelixis USD 39.06M 14.91M Jun/2026
Glaxosmithkline GBP 14.34B 6.39B Mar/2026
Heron Therapeutics USD 11.64M 2.67M Jun/2026
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
Ironwood Pharmaceuticals USD 3.24M 339K Mar/2026
Lexicon Pharmaceuticals USD 3M 87K Mar/2026
Lonza CHF 471M 3M Dec/2024
Merck USD 3.83B 36M Jun/2026
Moderna USD 167M 6M Jun/2026
Myriad Genetics USD 30.4M 2.2M Jun/2026
Nektar Therapeutics USD 10.03M 744K Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Pacira USD 17.51M 3.5M Jun/2026
Pfizer USD 4.58B 75M Jun/2026
PTC Therapeutics USD 41.59M 1.14M Sep/2026
Sanofi EUR 23.6B 888M Jun/2026
Sarepta Therapeutics USD 50.98M 19.39M Jun/2026
United Therapeutics USD 497.8M 500K Jun/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024